Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689636 · ClinicalTrials.gov registry record · Phase 1
Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
A Phase 1 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01689636: Completed Phase 1 study, sponsored by Endocyte.
NCT01689636 is a Phase 1 study that has completed, run by Endocyte. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689636, a Phase 1 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-label, single-center, single-treatment group, baseline-controlled (for safety) study of the safety and biodistribution of Technetium Tc 99m EC20 in four normal subjects and four subjects with known or suspected ovarian cancer.
Interventions
- DRUG Tc 99m EC20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2000-08 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689636
The ClinicalTrials.gov registry entry for NCT01689636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc 99m EC20 is the first listed.
NCT01689636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689636 about?
NCT01689636 is a clinical study titled "Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients". Open-label, single-center, single-treatment group, baseline-controlled (for safety) study of the safety and biodistribution of Technetium Tc 99m EC20 in four normal subjects and four subjects with known or suspected ovarian cancer.
What is the current status of trial NCT01689636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2000-08. Estimated completion is 2002-07.
What interventions are being tested in trial NCT01689636?
The interventions under investigation include: Tc 99m EC20 (DRUG).
Who is sponsoring clinical trial NCT01689636?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.